A Phase 4 interventional study of Aspirin and Clopidogrel in Ischemic Stroke, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing aspirin in Ischemic Stroke — 7 open to participants now, 7 under way, 2 of them phase 3. Aspirin · Ischemic Stroke.
Among the 23 studies testing aspirin in Ischemic Stroke, this one is the 10th largest by planned enrollment, is one of 2 that started in 2023, is one of 10 in phase 4, and was the 16th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →7 of the 23 studies testing aspirin in Ischemic Stroke are open now, in 5 countries. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18+
Rajaie Cardiovascular Medical and Research Center · Sites in Iran, Islamic Republic of
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18+
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 472 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 400 across the 23 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 23 have an industry lead sponsor. The 10 most frequent:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.
13 studies in Ischemic Stroke by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: 11 open now, 11 under way, 5 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 13 studies in Ischemic Stroke by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is one of 3 that started in 2023, is the only one in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 3rd registered.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University’s Ischemic Stroke studies by the year they started, since 2017.
2 of the studies testing aspirin in Ischemic Stroke that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT05910125Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing aspirin in Ischemic Stroke, from their registry updates:
Among Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University’s 13 in Ischemic Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving dual antiplatelet therapy immediately after randomization (Oral aspirin 100mg+clopidogrel 300mg, Day 1). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90) and clopidogrel 75mg/d (Day 2-21), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.
Drug: Aspirin · Drug: Clopidogrel
Receiving intravenous thrombolysis immediately after randomization (Intravenous alteplase, 0.9mg/kg, a maximum dosage of 90mg). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.
Drug: Alteplase
See arm/group descriptions.
See arm/group descriptions.
See arm/group descriptions.
The modified Rankin Scale score (mRS) 0-1
The proportion of the modified Rankin Scale score (mRS) 0-1 at 90 days.
Time frame: 90(±7) days
The modified Rankin Scale score (mRS) 0-1
The proportion of the modified Rankin Scale score (mRS) 0-1 at 7 days or discharge (whichever occurred first).
Time frame: 7(±1) days
Early neurological deterioration
The incidence of early neurological deterioration at 7 days.
Time frame: 7(±1) days
Recurrent stroke
The incidence of recurrent stroke at 90 days.
Time frame: 90(±7) days
SAFETY OUTCOME: Symptomatic intracranial hemorrhage
Symptomatic intracranial hemorrhage within 36 hours (according to Heidelberg criteria)
Time frame: 24 (±12) hours
SAFETY OUTCOME: Mortality
Mortality at 90 days
Time frame: 90(±7) days
SAFETY OUTCOME: Any intracranial hemorrhage
Any intracranial hemorrhage within 36 hours (according to Heidelberg criteria)
Time frame: 24 (±12) hours
Start is estimated for Jul 2023; primary completion for Jul 2027, 48 months later.
Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 48 months is above that.
Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aspirin · Clopidogrel
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →